Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022
29.09.2022 - Carlsbad, CA, Sept. 29, 2022 (GLOBE NEWSWIRE) - Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted ...
Michael Dawson Jenene Thomas Congress Program Planner Rectal Surgery Bowel Function Chief Medical Officer
Source: wallstreet-online.de